ISIN | LU2050612402 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
Peculiarities |
Current Price * | 90.19 USD | 25.07.2025 |
---|---|---|
Previous Price * | 91.30 USD | 24.07.2025 |
52 Week High * | 108.58 USD | 26.07.2024 |
52 Week Low * | 72.17 USD | 09.04.2025 |
NAV * | 90.19 USD | 25.07.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 351,316,921 | |
Unit/Share Assets *** | 95,217,903 | |
Trading Information SIX |
YTD Performance | +0.02% |
31.12.2024 - 25.07.2025
31.12.2024 25.07.2025 |
---|---|---|
YTD Performance (in CHF) | -12.35% |
31.12.2024 - 25.07.2025
31.12.2024 25.07.2025 |
1 month | +8.14% |
25.06.2025 - 25.07.2025
25.06.2025 25.07.2025 |
3 months | +9.84% |
25.04.2025 - 25.07.2025
25.04.2025 25.07.2025 |
6 months | -2.77% |
27.01.2025 - 25.07.2025
27.01.2025 25.07.2025 |
1 year | -15.69% |
25.07.2024 - 25.07.2025
25.07.2024 25.07.2025 |
2 years | -12.84% |
25.07.2023 - 25.07.2025
25.07.2023 25.07.2025 |
3 years | -20.61% |
25.07.2022 - 25.07.2025
25.07.2022 25.07.2025 |
5 years | -36.61% |
27.07.2020 - 25.07.2025
27.07.2020 25.07.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Ionis Pharmaceuticals Inc | 3.34% | |
---|---|---|
Alnylam Pharmaceuticals Inc | 3.30% | |
Novartis AG Registered Shares | 3.25% | |
PTC Therapeutics Inc | 3.12% | |
Gilead Sciences Inc | 3.08% | |
CRISPR Therapeutics AG | 2.84% | |
Amgen Inc | 2.83% | |
Astellas Pharma Inc | 2.81% | |
Wuxi AppTec Co Ltd | 2.76% | |
Lonza Group Ltd | 2.65% | |
Last data update | 30.06.2025 |
TER *** | 0.94% |
---|---|
TER date *** | 31.12.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.72% |
Ongoing Charges *** | 0.94% |
SRRI ***
|
|
SRRI date *** | 30.06.2025 |